Rani Therapeutics Holdings (RANI) Liabilities and Shareholders Equity (2020 - 2026)

Rani Therapeutics Holdings has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $60.8 million in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 260.06% year-over-year to $60.8 million in Q2 2026; TTM through Jun 2026 was $181.5 million, a 49.74% increase from a year earlier, with the FY2025 full-year figure at $58.6 million, up 60.02% from the prior year.
• Liabilities and Shareholders Equity was $60.8 million for Q2 2026 at Rani Therapeutics Holdings, up from $51.9 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $115.3 million in Q1 2022, with the low at $10.1 million in Q3 2025.
• Average Liabilities and Shareholders Equity over 5 years is $63.6 million, with a median of $58.3 million recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity sank 76.71% in 2025, then jumped 260.06% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $108.0 million in 2022, then tumbled by 46.39% to $57.9 million in 2023, then plunged by 36.75% to $36.6 million in 2024, then jumped by 60.02% to $58.6 million in 2025, then grew by 3.79% to $60.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $60.8 million (Q2 2026), $51.9 million (Q1 2026), and $58.6 million (Q4 2025), per Business Quant data.